Primary Ciliary Dyskinesia Market in 7MM Set to Grow Through 2034 Amid Expanding Pipeline Therapies

Published Date :

  • The Primary Ciliary Dyskinesia (PCD) market across the 7MM was valued at approximately USD 101 million in 2023. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Primary Ciliary Dyskinesia landscape.
  • In 2023, the United States accounted for approximately USD 36 million of the overall PCD market size among the 7MM, alongside nearly 1,800 diagnosed prevalent cases in the country.
  • In 2023, the 7MM accounted for nearly 70,000 total prevalent cases of Primary Ciliary Dyskinesia. The age-specific case distribution in the United States spans four groups - 0-5, 6-20, 21-40, and >40 - with the 6-20 age group accounting for the highest number of prevalent cases among all groups.

Primary Ciliary Dyskinesia Market Size

DelveInsight's report "Primary Ciliary Dyskinesia – Market Insight, Epidemiology, and Market Forecast – 2034" provides a comprehensive analysis of the Primary Ciliary Dyskinesia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, diagnosed cases, and patient demographics across key regions.

Additionally, it examines Primary Ciliary Dyskinesia market dynamics, current treatment practices, emerging drugs, and market share of individual therapies. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Primary Ciliary Dyskinesia market outlook, drug uptake, and treatment scenario, Click here; Primary Ciliary Dyskinesia Market Forecast

Some of the key facts of the Primary Ciliary Dyskinesia Market Report:

Key Primary Ciliary Dyskinesia Companies: Parion Sciences, ReCode Therapeutics Key Primary Ciliary Dyskinesia Therapies: P-1037 (Idrevloride/VX-371), RCT1100 In June 2024, the US FDA granted Orphan Drug Designation for RCT1100 for the treatment of primary ciliary dyskinesia (PCD). In April 2023, Parion Sciences announced a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) for the Paediatric Investigation Plan (PIP) for Idrevloride Inhalation Solution for the treatment of PCD. There is no single, standard treatment for Primary Ciliary Dyskinesia; management is multifaceted and tailored to the individual's symptoms and disease progression, focusing on managing respiratory symptoms, preventing infections, and preserving lung function.

Primary Ciliary Dyskinesia Overview

Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder affecting motile cilia, leading to various clinical manifestations such as respiratory distress in term neonates, chronic oto-sino-pulmonary disease, male infertility, and organ laterality defects in approximately 50% of cases. Historically, this syndrome was identified by a triad of chronic sinusitis, bronchiectasis, and situs inversus, known as Kartagener syndrome. Later, Afzelius discovered that patients with this syndrome had "immotile" cilia with defective ciliary ultrastructure. It was eventually recognized that most patients exhibited stiff, uncoordinated, and ineffective ciliary beats, leading to the term "primary ciliary dyskinesia" to distinguish this genetic disorder from secondary or acquired ciliary defects.

Get a Free sample for the Primary Ciliary Dyskinesia Market Forecast, Size & Share Analysis Report: Primary Ciliary Dyskinesia Market Report Sample

Key Trends in Primary Ciliary Dyskinesia Market

Growing Primary Ciliary Dyskinesia Patient Pool: In 2023, the 7MM accounted for nearly 70K prevalent cases of Primary Ciliary Dyskinesia, according to DelveInsight's analysis. The increasing availability of advanced diagnostic techniques and greater disease awareness are expected to further improve case detection, leading to a steadily expanding patient pool during the forecast period.

Established Therapies Supporting Primary Ciliary Dyskinesia Care: Antibiotics remain the cornerstone of PCD management, with oral antibiotics prescribed for mild infections and intravenous (IV) antibiotics used for severe or persistent cases. Alongside these, bronchodilators and anti-inflammatory agents are widely adopted to reduce airway obstruction and inflammation, supporting long-term management and improved quality of life for patients.

Advancements in Primary Ciliary Dyskinesia Pipeline Therapies: The PCD treatment pipeline is growing, with several novel therapies under investigation, including P-1037/VX-371 (Parion Sciences), RCT1100 (ReCode Therapeutics), and ETH-42 (Ethris GmbH). These therapies aim to target the underlying genetic and functional causes of PCD, offering hope for disease-modifying treatment options beyond symptomatic care.

Expanding Clinical Trial Activity in Primary Ciliary Dyskinesia: A robust clinical research ecosystem is shaping the future of PCD care, with several companies investing in innovative therapies. Increased trial activity across the U.S. and Europe highlights the growing industry and academic interest in addressing this rare respiratory condition, which has historically been underdiagnosed and undertreated.

Primary Ciliary Dyskinesia Epidemiology

The Primary Ciliary Dyskinesia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034, covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

In 2023, the United States accounted for nearly 1,800 diagnosed prevalent cases of Primary Ciliary Dyskinesia. Among all age groups, the 6-20 category accounted for the highest number of cases in the United States. When segmented by clinical manifestations — Pulmonary Disease, Situs Abnormality, Infertility, Eye Disorders, and other manifestations — Pulmonary Disease accounted for the highest number of cases in the United States.

Primary Ciliary Dyskinesia Epidemiology Segmentation

The Primary Ciliary Dyskinesia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of Primary Ciliary Dyskinesia Total Diagnosed Prevalent Cases of Primary Ciliary Dyskinesia Age-specific Cases of Primary Ciliary Dyskinesia Total Prevalence of Primary Ciliary Dyskinesia by Pathogenic Variants in Gene Total Prevalence of Primary Ciliary Dyskinesia by Clinical Manifestations

Unlock comprehensive insights! Click Here to Purchase the Full Report @ Primary Ciliary Dyskinesia Epidemiology Report

Recent Development in the Primary Ciliary Dyskinesia Treatment Landscape

  • In June 2024, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for RCT1100 for the treatment of primary ciliary dyskinesia (PCD). 
  • In April 2023, Parion Sciences announced receipt of a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) for the Paediatric Investigation Plan (PIP) for Idrevloride Inhalation Solution, for the treatment of primary ciliary dyskinesia (PCD).

Primary Ciliary Dyskinesia Drugs Uptake and Pipeline Development Activities

The drug chapter segment of the Primary Ciliary Dyskinesia report encloses a detailed analysis of the mid-stage pipeline drugs and early-stage drugs. The current key players include Parion Sciences and ReCode Therapeutics. The drug chapter also helps understand the Primary Ciliary Dyskinesia clinical trial details, pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

There are currently no PCD-specific approved therapies that restore ciliary function, and treatment is drawn from those used for cystic fibrosis and non-CF bronchiectasis, such as CFTR modulators. Treatment for PCD primarily focuses on managing symptoms and preventing complications, with airway clearance techniques, chest physiotherapy (CPT), and Positive Expiratory Pressure (PEP) devices forming a key component of care.

Primary Ciliary Dyskinesia Therapies and Key Companies

  • P-1037: Parion Sciences

P-1037 (Idrevloride/VX-371) is an inhaled investigational epithelial sodium channel (ENaC) inhibitor being developed by Parion for the treatment of PCD. ENaC inhibitors are designed to block the sodium channels on the airway surface, thus both blocking the absorption of water and stimulating fluid secretion in people with functional cystic fibrosis transmembrane conductance regulator (CFTR). Inhaled Idrevloride Solution is formulated to hydrate the mucus in the lung, thereby improving clearance of mucus by cough, thus improving lung function in people with PCD and other respiratory diseases who accumulate excessively concentrated mucus in their lungs. Idrevloride has been well-tolerated in multiple clinical trials in healthy volunteers and patients with muco-obstructive lung diseases, including primary ciliary dyskinesia. Currently, P-1037 is being investigated in a Phase II trial for treating Primary Ciliary Dyskinesia.

  • RCT1100: ReCode Therapeutics
  • ETH-42: Ethris GmbH

Discover more about therapies set to grab major Primary Ciliary Dyskinesia market share @ Primary Ciliary Dyskinesia Treatment Landscape

Primary Ciliary Dyskinesia Market Drivers

Growing Primary Ciliary Dyskinesia Patient Pool: Increasing availability of advanced diagnostic techniques and greater disease awareness are expected to improve case detection, expanding the patient pool. Established Therapies Supporting Care: Antibiotics, bronchodilators, and anti-inflammatory agents remain the cornerstone of PCD management, supporting long-term outcomes. Advancements in Pipeline Therapies: Novel candidates such as P-1037/VX-371, RCT1100, and ETH-42 target the underlying genetic and functional causes of PCD. Expanding Clinical Trial Activity: Growing industry and academic investment in innovative therapies is increasing trial activity across the U.S. and Europe for this historically underdiagnosed condition.

Scope of the Primary Ciliary Dyskinesia Market Report

  • Study Period: 2020–2034
  • Forecast Period: 2024–2034
  • Geographies Covered: The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
  • Key Primary Ciliary Dyskinesia Companies: Parion Sciences, ReCode Therapeutics
  • Key Primary Ciliary Dyskinesia Therapies: P-1037, RCT1100
  • Primary Ciliary Dyskinesia Epidemiology Segmentation:
  • Total Prevalent Cases
  • Total Diagnosed Prevalent Cases
  • Age-specific Cases
  • Total Prevalence by Pathogenic Variants in Gene
  • Total Prevalence by Clinical Manifestations
  • Primary Ciliary Dyskinesia Market Segmentation: Region
  • Therapies Analysis: KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, Unmet Needs

To know more about Primary Ciliary Dyskinesia companies working in the treatment market, visit @ Primary Ciliary Dyskinesia Clinical Trials and Therapeutic Assessment

Need more?

  • ✅ Connect with our analyst to learn how this research was developed
  • ✅ Expand the scope with additional segments or countries through free customization
  • ✅ Discover how this report can directly influence your business growth
Request Free Sample

Related Reports

report image delveinsight

Primary Ciliary Dyskinesia Market Insight, Epidemiology And Market Forecast - 2034

report image delveinsight

Primary Ciliary Dyskinesia (PCD) - Pipeline Insight, 2025

GET A FREE SAMPLE

This sample page is packed with key market insights, including trends, key growth drivers, opportunities, data-driven forecasts, and much more. Explore the data yourself.

Or view our licence options:

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports